{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:11:16Z","timestamp":1767139876318,"version":"build-2238731810"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Migr\u00e4ne ist die h\u00e4ufigste neurologische Erkrankung und kann mit einem hohen Grad der Beeintr\u00e4chtigung einhergehen. Neben nichtmedikament\u00f6sen Ans\u00e4tzen zur Reduktion der Migr\u00e4nefrequenz stehen medikament\u00f6se Migr\u00e4neprophylaxen zur Verf\u00fcgung. Zur Indikation und Anwendung liegen evidenzbasierte Leitlinien der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG) und Deutschen Gesellschaft f\u00fcr Neurologie (DGN), \u00d6sterreichischen Kopfschmerzgesellschaft (\u00d6KSG) sowie Schweizer Kopfwehgesellschaft (SKG) vor. F\u00fcr therapierelevante Fragen wie z.\u202fB. der notwendigen und sinnvollen Dauer einer medikament\u00f6sen Migr\u00e4neprophylaxe k\u00f6nnen aus bisherigen Studiendaten keine R\u00fcckschl\u00fcsse gezogen werden. Ziel dieser \u00dcbersicht ist die Formulierung von Empfehlungen zur Therapiedauer bei wirksamer medikament\u00f6ser Migr\u00e4neprophylaxe, die die aktuelle Datenlage und \u2013\u00a0bei fehlenden Daten\u00a0\u2013 die Expertenmeinungen ber\u00fccksichtigen.<\/jats:p>","DOI":"10.1007\/s00482-022-00671-9","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T06:03:44Z","timestamp":1666764224000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Konsensusstatement der Migr\u00e4ne- und Kopfschmerzgesellschaften (DMKG, \u00d6KSG &amp; SKG) zur Therapiedauer der medikament\u00f6sen Migr\u00e4neprophylaxe","Consensus statement of the migraine and headache societies (DMKG, \u00d6KSG, and SKG) on the duration of pharmacological  migraine prophylaxis"],"prefix":"10.1007","volume":"37","author":[{"given":"Gudrun","family":"Go\u00dfrau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"F\u00f6rderreuther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Ruschil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Freilinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Malzacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dresler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Schankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas R.","family":"Gantenbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Br\u00f6ssner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Zebenholzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim P.","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"5","key":"671_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00482-017-0214-1","volume":"31","author":"P Kropp","year":"2017","unstructured":"Kropp\u00a0P, Meyer\u00a0B, Dresler\u00a0T, Fritsche\u00a0G, Gaul\u00a0C, Niederberger\u00a0U et\u00a0al (2017) Relaxation techniques and behavioural therapy for the treatment of migraine: Guidelines from the German Migraine and Headache Society. Schmerz 31(5):433\u2013447. https:\/\/doi.org\/10.1007\/s00482-017-0214-1","journal-title":"Schmerz"},{"issue":"1","key":"671_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner\u00a0TJ, Stovner\u00a0LJ, Jensen\u00a0R, Uluduz\u00a0D, Katsarava\u00a0Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J\u00a0Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"issue":"10","key":"671_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford\u00a0JH, Jackson\u00a0J, Milligan\u00a0G, Cotton\u00a0S, Ahl\u00a0J, Aurora\u00a0SK (2017) A real-world analysis of migraine: A cross-sectional study of disease burden and treatment patterns. Headache 57(10):1532\u20131544. https:\/\/doi.org\/10.1111\/head.13202","journal-title":"Headache"},{"issue":"4","key":"671_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/head.14289","volume":"62","author":"L Harris","year":"2022","unstructured":"Harris\u00a0L, L\u2019Italien\u00a0G, Kumar\u00a0A, Seelam\u00a0P, LaVallee\u00a0C, Coric\u00a0V et al (2022) Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States. Headache 62(4):473\u2013481. https:\/\/doi.org\/10.1111\/head.14289","journal-title":"Headache"},{"key":"671_CR5","unstructured":"DMKG (2022) Mehr Kopfschmerzexpertise gew\u00fcnscht. https:\/\/www.attacke-kopfschmerzen.de\/news\/meldungen\/87-mehr-kopfschmerzexpertise-gewuenscht. Zugegriffen: 30.03.2022"},{"key":"671_CR6","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H-CGC Diener","year":"2018","unstructured":"Diener\u00a0H\u2011CGC, Kropp\u00a0P et al (2018) Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne. In: S1-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (www.dgn.org\/leitlinien (abgerufen am 11.04.2022))"},{"key":"671_CR7","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"H-C Diener","year":"2019","unstructured":"Diener\u00a0H\u2011C (2019) MAea. Prophylaxe der Migr\u00e4ne mit monoklonalen Antik\u00f6rpern gegen CGRP oder den CGRP-Rezeptor, Erg\u00e4nzung der S1-Leitlinie Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (www.dgn.org\/leitlinien (abgerufen am 06.04.2022))"},{"issue":"1","key":"671_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst\u00a0F, Van Deun\u00a0L, Van Dycke\u00a0A, Paemeleire\u00a0K, Reuter\u00a0U, Schoenen\u00a0J et\u00a0al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J\u00a0Headache Pain 22(1):128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2","journal-title":"J Headache Pain"},{"issue":"1","key":"671_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano\u00a0D, Lipton\u00a0RB, Scher\u00a0AI, Reed\u00a0ML, Stewart\u00a0WBF, Adams\u00a0AM et\u00a0al (2017) Fluctuations in episodic and chronic migraine status over the course of 1\u00a0year: implications for diagnosis, treatment and clinical trial design. J\u00a0Headache Pain 18(1):101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1","journal-title":"J Headache Pain"},{"issue":"6","key":"671_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp\u00a0Z, Dodick\u00a0DW, Varon\u00a0SF, Gillard\u00a0P, Hansen\u00a0RN, Devine\u00a0EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u2013488. https:\/\/doi.org\/10.1177\/0333102414547138","journal-title":"Cephalalgia"},{"issue":"4","key":"671_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld\u00a0AM, Bloudek\u00a0LM, Becker\u00a0WJ, Buse\u00a0DC, Varon\u00a0SF, Maglinte\u00a0GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"issue":"7","key":"671_CR12","doi-asserted-by":"publisher","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","volume":"10","author":"JL Jackson","year":"2015","unstructured":"Jackson\u00a0JL, Cogbill\u00a0E, Santana-Davila\u00a0R, Eldredge\u00a0C, Collier\u00a0W, Gradall\u00a0A et al (2015) A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS ONE 10(7):e130733. https:\/\/doi.org\/10.1371\/journal.pone.0130733","journal-title":"PLoS ONE"},{"issue":"3","key":"671_CR13","doi-asserted-by":"publisher","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","volume":"14","author":"JL Jackson","year":"2019","unstructured":"Jackson\u00a0JL, Kuriyama\u00a0A, Kuwatsuka\u00a0Y, Nickoloff\u00a0S, Storch\u00a0D, Jackson\u00a0W et al (2019) Beta-blockers for the prevention of headache in adults, a\u00a0systematic review and meta-analysis. PLoS ONE 14(3):e212785. https:\/\/doi.org\/10.1371\/journal.pone.0212785","journal-title":"PLoS ONE"},{"key":"671_CR14","doi-asserted-by":"publisher","first-page":"CD003225","DOI":"10.1002\/14651858.CD003225.pub2","volume":"2","author":"K Linde","year":"2004","unstructured":"Linde\u00a0K, Rossnagel\u00a0K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:CD3225. https:\/\/doi.org\/10.1002\/14651858.CD003225.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"671_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1474-4422(07)70272-7","volume":"6","author":"HC Diener","year":"2007","unstructured":"Diener\u00a0HC, Agosti\u00a0R, Allais\u00a0G, Bergmans\u00a0P, Bussone\u00a0G, Davies\u00a0B et al (2007) Cessation versus continuation of 6\u2011month migraine preventive therapy with topiramate (PROMPT): A\u00a0randomised, double-blind, placebo-controlled trial. Lancet Neurol 6(12):1054\u20131062. https:\/\/doi.org\/10.1016\/S1474-4422(07)70272-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"671_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1468-2982.1986.0601007.x","volume":"6","author":"PS Sorensen","year":"1986","unstructured":"Sorensen\u00a0PS, Hansen\u00a0K, Olesen\u00a0J (1986) A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 6(1):7\u201314. https:\/\/doi.org\/10.1046\/j.1468-2982.1986.0601007.x","journal-title":"Cephalalgia"},{"issue":"1","key":"671_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2165\/00003495-198427010-00002","volume":"27","author":"B Holmes","year":"1984","unstructured":"Holmes\u00a0B, Brogden\u00a0RN, Heel\u00a0RC, Speight\u00a0TM, Avery\u00a0GS (1984) Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic. Drugs 27(1):6\u201344. https:\/\/doi.org\/10.2165\/00003495-198427010-00002","journal-title":"Drugs"},{"issue":"5","key":"671_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1468-2982.1996.1605337.x","volume":"16","author":"A Nuti","year":"1996","unstructured":"Nuti\u00a0A, Lucetti\u00a0C, Pavese\u00a0N, Dell\u2019Agnello\u00a0G, Rossi\u00a0G, Bonuccelli\u00a0U (1996) Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients. Cephalalgia 16(5):337\u2013340. https:\/\/doi.org\/10.1046\/j.1468-2982.1996.1605337.x","journal-title":"Cephalalgia"},{"issue":"Suppl 8","key":"671_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/03331024880080S804","volume":"8","author":"JM Martinez-Lage","year":"1988","unstructured":"Martinez-Lage\u00a0JM (1988) Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia 8(Suppl 8):15\u201320. https:\/\/doi.org\/10.1177\/03331024880080S804","journal-title":"Cephalalgia"},{"issue":"6","key":"671_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1046\/j.1468-2982.1991.1106251.x","volume":"11","author":"C Wober","year":"1991","unstructured":"Wober\u00a0C, Wober-Bingol\u00a0C, Koch\u00a0G, Wessely\u00a0P (1991) Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 11(6):251\u2013256. https:\/\/doi.org\/10.1046\/j.1468-2982.1991.1106251.x","journal-title":"Cephalalgia"},{"key":"671_CR21","unstructured":"Fachinformation Flunarizin. (7. Apr. 2019 ). https:\/\/www.abz.de\/assets\/products\/de\/label\/Flunarizin-CT%205%20mg%20Hartkapseln%20-%202.pdf?pzn=7320564. Zugegriffen: 30.03.2022"},{"key":"671_CR22","unstructured":"https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Zulassung\/BereitsZugelAM\/offlabel\/Bewertungen\/Valproinsaeure_Addendum-3_08-11-2021.pdf?__blob=publicationFile. Zugegriffen: 30.03.2022"},{"issue":"4","key":"671_CR23","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1212\/wnl.44.4.647","volume":"44","author":"R Jensen","year":"1994","unstructured":"Jensen\u00a0R, Brinck\u00a0T, Olesen\u00a0J (1994) Sodium valproate has a\u00a0prophylactic effect in migraine without aura: a\u00a0triple-blind, placebo-controlled crossover study. Neurology 44(4):647\u2013651. https:\/\/doi.org\/10.1212\/wnl.44.4.647","journal-title":"Neurology"},{"issue":"1","key":"671_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","volume":"51","author":"JR Couch","year":"2011","unstructured":"Couch\u00a0JR, Amitriptyline Versus Placebo Study Group (2011) Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 51(1):33\u201351. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01800.x","journal-title":"Headache"},{"issue":"1","key":"671_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-020-01113-6","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello\u00a0R, Guerzoni\u00a0S, Baraldi\u00a0C, Evangelista\u00a0L, Frattale\u00a0I, Marini\u00a0C et al (2020) Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. J\u00a0Headache Pain 21(1):40. https:\/\/doi.org\/10.1186\/s10194-020-01113-6","journal-title":"J Headache Pain"},{"key":"671_CR26","doi-asserted-by":"publisher","first-page":"647995","DOI":"10.3389\/fneur.2021.647995","volume":"12","author":"C Baraldi","year":"2021","unstructured":"Baraldi\u00a0C, Ornello\u00a0R, Favoni\u00a0V, Sacco\u00a0S, Caponnetto\u00a0V, Pierangeli\u00a0G et al (2021) Chronic migraine and medication overuse headache worsening after OnabotulinumtoxinA withdrawn due to the severe acute respiratory syndrome-Coronavirus\u20112 pandemic. Front Neurol 12:647995. https:\/\/doi.org\/10.3389\/fneur.2021.647995","journal-title":"Front Neurol"},{"key":"671_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-016-0634-9","volume":"17","author":"S Guerzoni","year":"2015","unstructured":"Guerzoni\u00a0S, Pellesi\u00a0L, Baraldi\u00a0C, Pini\u00a0LA (2015) Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J\u00a0Headache Pain 17:48. https:\/\/doi.org\/10.1186\/s10194-016-0634-9","journal-title":"J Headache Pain"},{"issue":"10","key":"671_CR28","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/0333102414561873","volume":"35","author":"E Cernuda-Morollon","year":"2015","unstructured":"Cernuda-Morollon\u00a0E, Ramon\u00a0C, Larrosa\u00a0D, Alvarez\u00a0R, Riesco\u00a0N, Pascual\u00a0J (2015) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 35(10):864\u2013868. https:\/\/doi.org\/10.1177\/0333102414561873","journal-title":"Cephalalgia"},{"issue":"8","key":"671_CR29","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/head.13630","volume":"59","author":"J Ching","year":"2019","unstructured":"Ching\u00a0J, Tinsley\u00a0A, Rothrock\u00a0J (2019) Prognosis following discontinuation of OnabotulinumA therapy in \u201csuper-responding\u201d chronic migraine patients. Headache 59(8):1279\u20131285. https:\/\/doi.org\/10.1111\/head.13630","journal-title":"Headache"},{"key":"671_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15260","author":"LF Iannone","year":"2022","unstructured":"Iannone\u00a0LF, Fattori\u00a0D, Benemei\u00a0S, Chiarugi\u00a0A, Geppetti\u00a0P, De Cesaris\u00a0F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15260","journal-title":"Eur J Neurol"},{"key":"671_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-05870-x","author":"S Guerzoni","year":"2022","unstructured":"Guerzoni\u00a0S, Baraldi\u00a0C, Pensato\u00a0U, Favoni\u00a0V, Lo Castro\u00a0F, Cainazzo\u00a0MM et al (2022) Chronic migraine evolution after 3\u00a0months from erenumab suspension: real-world-evidence-life data. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-022-05870-x","journal-title":"Neurol Sci"},{"issue":"1","key":"671_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-022-01417-9","volume":"23","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli\u00a0B, Terhart\u00a0M, Mecklenburg\u00a0J, Neeb\u00a0L, Overeem\u00a0LH, Siebert\u00a0A et al (2022) Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a\u00a03-month drug holiday: a\u00a0real-world experience. J\u00a0Headache Pain 23(1):40. https:\/\/doi.org\/10.1186\/s10194-022-01417-9","journal-title":"J Headache Pain"},{"issue":"1","key":"671_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","volume":"20","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli\u00a0B, Mussetto\u00a0V, Israel\u00a0H, Neeb\u00a0L, Reuter\u00a0U (2019) Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J\u00a0Headache Pain 20(1):66. https:\/\/doi.org\/10.1186\/s10194-019-1018-8","journal-title":"J Headache Pain"},{"issue":"6","key":"671_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer\u00a0VL, Wang\u00a0S, Voulgaropoulos\u00a0M, Skljarevski\u00a0V, Kovacik\u00a0A, Aurora\u00a0SK (2019) Effect of Galcanezumab following treatment cessation in patients with migraine: Results from 2 randomized phase 3 trials. Headache 59(6):834\u2013847. https:\/\/doi.org\/10.1111\/head.13508","journal-title":"Headache"},{"issue":"11\u201312","key":"671_CR35","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein\u00a0AR, Agosti\u00a0R, Gobbi\u00a0C, Flugel\u00a0D, Schankin\u00a0CJ, Viceic\u00a0D et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2014A\u00a0real-life cohort study. Cephalalgia 41(11\u201312):1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"671_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/03331024211046617","volume":"42","author":"B Raffaelli","year":"2022","unstructured":"Raffaelli\u00a0B, Terhart\u00a0M, Overeem\u00a0LH, Mecklenburg\u00a0J, Neeb\u00a0L, Steinicke\u00a0M et al (2022) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a\u00a0prospective, longitudinal cohort study. Cephalalgia 42(4\u20135):326\u2013334. https:\/\/doi.org\/10.1177\/03331024211046617","journal-title":"Cephalalgia"},{"issue":"1","key":"671_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s10194-021-01368-7","volume":"22","author":"M Terhart","year":"2021","unstructured":"Terhart\u00a0M, Mecklenburg\u00a0J, Neeb\u00a0L, Overeem\u00a0LH, Siebert\u00a0A, Steinicke\u00a0M et al (2021) Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J\u00a0Headache Pain 22(1):158. https:\/\/doi.org\/10.1186\/s10194-021-01368-7","journal-title":"J Headache Pain"},{"issue":"8","key":"671_CR38","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis\u00a0E, Affaitati\u00a0G, Frattale\u00a0I, Caponnetto\u00a0V, Pistoia\u00a0F, Giamberardino\u00a0MA et al (2021) Early outcomes of migraine after erenumab discontinuation: data from a\u00a0real-life setting. Neurol Sci 42(8):3297\u20133303. https:\/\/doi.org\/10.1007\/s10072-020-05022-z","journal-title":"Neurol Sci"},{"issue":"1","key":"671_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri\u00a0F, Brunelli\u00a0N, Messina\u00a0R, Costa\u00a0CM, Colombo\u00a0B, Torelli\u00a0P et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J\u00a0Headache Pain 22(1):154. https:\/\/doi.org\/10.1186\/s10194-021-01363-y","journal-title":"J Headache Pain"},{"issue":"12","key":"671_CR40","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2019.1671350","volume":"19","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli\u00a0B, Neeb\u00a0L, Reuter\u00a0U (2019) Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 19(12):1307\u20131317. https:\/\/doi.org\/10.1080\/14712598.2019.1671350","journal-title":"Expert Opin Biol Ther"},{"key":"671_CR41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fpsyt.2019.00504","volume":"10","author":"Y Pan","year":"2019","unstructured":"Pan\u00a0Y, Kinitz\u00a0T, Stapic\u00a0M, Nestoriuc\u00a0Y (2019) Minimizing drug adverse events by informing about the Nocebo effect-an experimental study. Front Psychiatry 10:504. https:\/\/doi.org\/10.3389\/fpsyt.2019.00504","journal-title":"Front Psychiatry"},{"key":"671_CR42","unstructured":"SKG-Therapieempfehlungen f\u00fcr prim\u00e4re Kopfschmerzen (Brosch\u00fcre 2021)\nhttps:\/\/www.headache.ch\/download\/Content_attachments\/FileBaseDoc\/SKG_Therapieempfehlungen_DE_19_WEB.pdfzugegriffen. Zugegriffen: 19.09.2022"},{"key":"671_CR43","first-page":"13","volume":"1","author":"AR","year":"2013","unstructured":"AR, SPG (2013) Positive Nebenwirkungen in der Migr\u00e4netherapie. Schweiz Z Psychiatr Neurol 1:13\u201315","journal-title":"Schweiz Z Psychiatr Neurol"},{"issue":"2","key":"671_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter\u00a0U, Ehrlich\u00a0M, Gendolla\u00a0A, Heinze\u00a0A, Klatt\u00a0J, Wen\u00a0S et al (2022) Erenumab versus topiramate for the prevention of migraine\u2014A\u00a0randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42(2):108\u2013118. https:\/\/doi.org\/10.1177\/03331024211053571","journal-title":"Cephalalgia"},{"key":"671_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2072","author":"Y Zhang","year":"2022","unstructured":"Zhang\u00a0Y, Xu\u00a0Y, Liu\u00a0S, Liang\u00a0J, Fan\u00a0S, Ding\u00a0M et al (2022) The Nocebo response in pharmacologic treatments of primary headache: A systematic review and meta-analysis. J\u00a0Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.2072","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"671_CR46","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00115-018-0534-0","volume":"89","author":"R Ruscheweyh","year":"2018","unstructured":"Ruscheweyh\u00a0R, Forderreuther\u00a0S, Gaul\u00a0C, Gendolla\u00a0A, Holle-Lee\u00a0D, Jurgens\u00a0T et al (2018) Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society. Nervenarzt 89(12):1355\u20131364. https:\/\/doi.org\/10.1007\/s00115-018-0534-0","journal-title":"Nervenarzt"},{"issue":"4\u20135","key":"671_CR47","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/03331024211047454","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury\u00a0D, Bansal\u00a0L, Duggal\u00a0A, Datta\u00a0D, Mundra\u00a0A, Krishnan\u00a0A et al (2022) TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 42(4\u20135):396\u2013408. https:\/\/doi.org\/10.1177\/03331024211047454","journal-title":"Cephalalgia"},{"issue":"4","key":"671_CR48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/head.14097","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton\u00a0RB, Cohen\u00a0JM, Galic\u00a0M, Seminerio\u00a0MJ, Yeung\u00a0PP, Aycardi\u00a0E et\u00a0al (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache 61(4):662\u2013672. https:\/\/doi.org\/10.1111\/head.14097","journal-title":"Headache"},{"issue":"5","key":"671_CR49","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/jnnp-2020-324396","volume":"92","author":"M Lanteri-Minet","year":"2021","unstructured":"Lanteri-Minet\u00a0M, Goadsby\u00a0PJ, Reuter\u00a0U, Wen\u00a0S, Hours-Zesiger\u00a0P, Ferrari\u00a0MD et al (2021) Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2\u20134 preventives were not useful: results from the LIBERTY study. J\u00a0Neurol Neurosurg Psychiatry 92(5):466\u2013472. https:\/\/doi.org\/10.1136\/jnnp-2020-324396","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Supplement","key":"671_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.48208\/HeadacheMed.2020.Supplement.27","volume":"11","author":"AEE Ambrosini","year":"2020","unstructured":"Ambrosini\u00a0AEE, Pascual\u00a0J, Rettiganti\u00a0M, Stroud\u00a0C, Day\u00a0K, Ford\u00a0J (2020) Effects of galcanezumab on acute medication use and health care resource utilization in treatment-resistant migraine: Results from randomized, double blind, placebo-controlled clinical trial, conquer. Headache Med 11(Supplement):27 (https:\/\/headachemedicine.com.br\/index.php\/hm\/article\/view\/112)","journal-title":"Headache Med"},{"key":"671_CR51","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1796-21.2022","author":"SR Krimmel","year":"2022","unstructured":"Krimmel\u00a0SR, DeSouza\u00a0DD, Keaser\u00a0ML, Sanjanwala\u00a0BM, Cowan\u00a0RP, Lindquist\u00a0MA et\u00a0al (2022) Three dimensions of association link migraine symptoms and functional connectivity. J\u00a0Neurosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.1796-21.2022","journal-title":"J Neurosci"},{"issue":"1","key":"671_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco\u00a0S, Amin\u00a0FM, Ashina\u00a0M, Bendtsen\u00a0L, Deligianni\u00a0CI, Gil-Gouveia\u00a0R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J\u00a0Headache Pain 23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","journal-title":"J Headache Pain"},{"issue":"5","key":"671_CR53","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp\u00a0Z, Dodick\u00a0DW, Varon\u00a0SF, Chia\u00a0J, Matthew\u00a0N, Gillard\u00a0P et\u00a0al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"issue":"4\u20135","key":"671_CR54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/03331024211048765","volume":"42","author":"LH Overeem","year":"2022","unstructured":"Overeem\u00a0LH, Peikert\u00a0A, Hofacker\u00a0MD, Kamm\u00a0K, Ruscheweyh\u00a0R, Gendolla\u00a0A et al (2022) Effect of antibody switch in non-responders to a\u00a0CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia 42(4\u20135):291\u2013301. https:\/\/doi.org\/10.1177\/03331024211048765","journal-title":"Cephalalgia"}],"updated-by":[{"DOI":"10.1007\/s00482-022-00691-5","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000}}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-022-00671-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-022-00671-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-022-00671-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T06:26:15Z","timestamp":1675146375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-022-00671-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["671"],"URL":"https:\/\/doi.org\/10.1007\/s00482-022-00671-9","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00482-022-00691-5","URL":"https:\/\/doi.org\/10.1007\/s00482-022-00691-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Go\u00dfrau: Vortragshonorare, Beratert\u00e4tigkeit Teva, Lilly, Novartis, Hormosan, Lundbeck, IMPP, Forschungsf\u00f6rderung DFG, Novartis, Kosing-Stiftung, TU Dresden, Ehrenamtliche Vizepr\u00e4sidentin DMKG. S.\u00a0F\u00f6rderreuther: Vortragshonorare, Beratert\u00e4tigkeit: Sanofi, TEVA, Novartis, Eli Lilly. Beratert\u00e4tigkeit: Hormosan, Lundbeck, Vortragshonorare: Allergan\/Abbvie. R.\u00a0Ruscheweyh: Vortragshonorare, Beratert\u00e4tigkeit, Unterst\u00fctzung f\u00fcr Kongressreisen: Hormosan, Novartis, Lilly, Lundbeck, Pharm-Allergan, Teva. V.\u00a0Ruschil: Forschungsf\u00f6rderung von Novartis. T.\u00a0Sprenger: Vortragshonorare, Beratert\u00e4tigkeit: Actelion\/Janssen Cilag, Biogen Idec, Bristol Myers Squibb, Electrocore, Eli Lilly, Merck, Roche, Sanofi, Novartis, Teva; die Honorare der genannten Aktivit\u00e4ten erhielt vollumf\u00e4nglich der Arbeitgeber (DKD Helios Klinik Wiesbaden) von T.\u00a0Sprenger. D.\u00a0Lewis: Vortragshonorare, Beratert\u00e4tigkeit: Allergan Pharma , Hormosan Pharma, Lilly, Lundbeck, Novartis Pharma und TEVA-Ratiopharm. K.\u00a0Kamm: Vortragshonorare: Novartis, TEVA, Lundbeck. T.\u00a0Freilinger: Forschungsf\u00f6rderung: Electrocore, Novartis Lilly, DFG, BMBF, Universit\u00e4t T\u00fcbingen, Vortragst\u00e4tigkeit, Beratert\u00e4tigkeit: Novartis, Teva; Vortragst\u00e4tigkeit: Lilly, Bayer, UCB. L.\u00a0Neeb: Vortragshonorare, Beratert\u00e4tigkeit: Hormosan, Lilly, Novartis, TEVA, Allergan, Forschungsf\u00f6rderung: Innovationsfonds, TEVA, Lilly. V.\u00a0Malzacher: keine Interessenkonflikte, Ehrenamtlicher Schatzmeister DMKG. U.\u00a0Meier: Vortragshonorare, Beratert\u00e4tigkeit: Biogen, BMS, Gaia AG, Janssen, Merck Healthcare Germany, Novartis, Roche. K.\u00a0Gehring: Vortragshonorare, Beratert\u00e4tigkeit: Janssen, Novartis, Merck, Roche, Hexal, Vorsitzender BVDN. T.\u00a0Kraya: Vortrags- oder Beratert\u00e4tigkeit: Allergan Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lilly, Novartis, Teva, Forschungsf\u00f6rderung, DFG, Innovationsfonds, BMBF, Allergan Pharma, Hormosan Pharma, Gr\u00fcnenthal, Lilly, Novartis, Teva, Ehrenamtlicher 2.\u00a0Vizepr\u00e4sident DMKG. T.\u00a0Dresler: Vortragshonorare, Beratert\u00e4tigkeit: Novartis, Teva, Hormosan. C.J.\u00a0Schankin: Vortragshonorare, Beratert\u00e4tigkeit, \u00dcbernahme von Reisekosten: Eli Lilly, Novartis, TEVA Pharmaceuticals, Lundbeck, Allergan, Almirall, Amgen, MindMed, Gr\u00fcnenthal; Teilzeitanstellung: Zynnon; Forschungsf\u00f6rderung: DMKG, Eye on Vision Foundation, Baasch Medicus Foundation. A.R.\u00a0Gantenbein: Vortragshonorare, Beratert\u00e4tigkeit: Allergan\/Abbvie, Almirall, BioMed, Curatis, Eli Lilly, Gr\u00fcnenthal, Lundbeck, Neurolite, Novartis\/Amgen, Sanofi, Teva\/Mepha sowie f\u00fcr Aus- und Weiterbildung von medinform, MedScape, SIM. G.\u00a0Br\u00f6ssner: Vortragst\u00e4tigkeit: Lilly, TEVA, Novartis, Gr\u00fcnenthal; Beratungst\u00e4tigkeit: Lilly, TEVA, Novartis, Pfizer, Abbvie, Lundbeck; Forschungsf\u00f6rderung: TEVA. K.\u00a0Zebenholzer: Vortragshonorare, Beratert\u00e4tigkeit: Lundbeck, Gr\u00fcnenthal, Novartis Pharma, Eli Lilly, Teva Ratiopharm, Abbvie, Pfizer, MedAhead, vielgesundheit.at, Stada, MedMedia, Sanofi Genzyme; \u00dcbernahme von Reisekosten, Kongressgeb\u00fchren: MedAhead, \u00d6sterreichische Gesellschaft f\u00fcr Neurologie, \u00d6sterreichische Kopfschmerzgesellschaft, Eli Lilly, Sanofi Genzyme, Bristol Myers Squibb\/Celgene. H.\u2011C.\u00a0Diener: Vortragshonorare, Beratert\u00e4tigkeit: Abbvie, Ipsen Pharma, Lilly, Lundbeck, Novartis, Pfizer, TEVA und Weber & Weber; Forschungsf\u00f6rderung: DFG, BMBF. C.\u00a0Gaul: Abbvie-Allergan Pharma, TEVA-Ratiopharm, Lilly, Novartis Pharma, Hormosan Pharma, Weber & Weber, Lundbeck, Perfood und Gr\u00fcnenthal; Forschungsf\u00f6rderung: DFG; Ehrenamtlicher Generalsekret\u00e4r der DMKG. T.P.\u00a0J\u00fcrgens: Vortragshonorare, Beratert\u00e4tigkeit: Abbvie\/Allergan, Gr\u00fcnenthal, Hormosan, Lilly, Lundbeck, Novartis, Sanofi, TEVA; Tantiemen f\u00fcr Buchartikel von Elsevier und Springer; Forschungsf\u00f6rderung: Innovationsfonds, Europ\u00e4ische Union (EFRE), Novartis; Ehrenamtlicher Pr\u00e4sident der DMKG; Associate Editor Frontiers in Neurology, Mitglied Editorial Boards Journal of Headache and Pain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}